SCHEMBL13928890

SCHEMBL13928890

CCOC(=O)N1C(=O)C(=CC2CCCC2)c2ccc(Cl)cc21

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ APP P05067 2/20 0.43
▸ SNCA P37840 2/20 0.43
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ MAPK1 P28482 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ TSHR P16473 3/20 0.38
▸ RECQL P46063 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ TP53 P04637 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ CASP3 P42574 2/20 0.37
▸ TGM2 P21980 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3363641 0.99 MAPT (0.42) MAPTAPPSNCAMEN1KMT2A
SCHEMBL13928892 0.99 MAPT (0.42) MAPTAPPSNCAMEN1KMT2A
SCHEMBL3366620 0.83 ALDH1A1 (0.38) MAPTKMT2AMAPK1ALDH1A1GAA
SCHEMBL1022200 0.81 MAPT (0.60) MAPTAPPSNCAMEN1KMT2A
SCHEMBL4709524 0.81 MAPT (0.60) MAPTAPPSNCAMEN1KMT2A
SCHEMBL1022199 0.81 MAPT (0.60) MAPTAPPSNCAMEN1KMT2A
SCHEMBL8031160 0.78 MAPT (0.60) MAPTAPPSNCAMEN1KMT2A
SCHEMBL8226301 0.78 MAPT (0.54) MAPTAPPSNCAMEN1KMT2A
SCHEMBL4719164 0.78 MAPT (0.54) MAPTAPPSNCAMEN1KMT2A
SCHEMBL3361587 0.74 MAPT (0.44) MAPTAPPSNCAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 — — US disclosed
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 — — US disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 — — US disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 — — US disclosed
WO-2007104664-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-09-20 — — WO disclosed
US-20070213341-A1 Spiroindolinone derivatives CHEN LI 2007-09-13 — — US disclosed
US-20070213341-A1 Spiroindolinone derivatives CHEN LI 2007-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES RB1, PKD1, KRAS MAPT 4581/4885APP 4782/4885SNCA 2624/4885
US-20070213341-A1 Spiroindolinone derivatives MKI67, PKD1, RCC2 MAPT 4139/4885APP 4835/4885SNCA 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback